Literature DB >> 16769394

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.

Ron Shapiro1, Demetrius Ellis, Henkie P Tan, Michael L Moritz, Amit Basu, Abhay N Vats, Akhtar S Khan, Edward A Gray, Adrianna Zeevi, Corde McFeaters, Gerri James, Mary Jo Grosso, Amadeo Marcos, Thomas E Starzl.   

Abstract

OBJECTIVE: Heavy post-transplant immunosuppression may contribute to long-term immunosuppression dependence by subverting tolerogenic mechanisms; thus, we sought to determine if this undesirable consequence could be mitigated by pretransplant lymphoid depletion and minimalistic post-transplant monotherapy. STUDY
DESIGN: Lymphoid depletion in 17 unselected pediatric recipients of live (n = 14) or deceased donor kidneys (n = 3) was accomplished with antithymocyte globulin (ATG) (n = 8) or alemtuzumab (n = 9). Tacrolimus was begun post-transplantation with subsequent lengthening of intervals between doses (spaced weaning). Maintenance immunosuppression, morbidity, graft function, and patient/graft survival were collated.
RESULTS: Steroids were added temporarily to treat rejection in two patients (both ATG subgroup) or to treat hemolytic anemia in two others. After 16 to 31 months (mean 22), patient and graft survival was 100% and 94%, respectively. The only graft loss was in a nonweaned noncompliant recipient. In the other 16, serum creatinine was 0.85 +/- 0.35 mg/dL and creatinine clearance was 90.8 +/- 22.1 mL/1.73 m2. All 16 patients are on monotherapy (15 tacrolimus, one sirolimus), and 14 receive every other day or 3 times per week doses. There were no wound or other infections. Two patients developed insulin-dependent diabetes.
CONCLUSION: The strategy of lymphoid depletion and minimum post-transplant immunosuppression appears safe and effective for pediatric kidney recipients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769394      PMCID: PMC2955284          DOI: 10.1016/j.jpeds.2006.01.008

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  34 in total

Review 1.  Transplantation tolerance from a historical perspective.

Authors:  T E Starzl; R M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

Review 2.  Cell migration, chimerism, and graft acceptance.

Authors:  T E Starzl; A J Demetris; N Murase; S Ildstad; C Ricordi; M Trucco
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

Review 3.  The unfinished legacy of liver transplantation: emphasis on immunology.

Authors:  Thomas E Starzl; Fadi G Lakkis
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 4.  Rethinking chronic allograft nephropathy: the concept of accelerated senescence.

Authors:  P F Halloran; A Melk; C Barth
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

5.  Renal homotransplantation in pediatric patients.

Authors:  J R Lilly; G Giles; R Hurwitz; G Schroter; H Takagi; S Gray; I Penn; C G Halgrimson; T E Starzl
Journal:  Pediatrics       Date:  1971-03       Impact factor: 7.124

6.  Renal homotransplantation in children.

Authors:  R N Fine; B M Korsch; Q Stiles; H Riddell; H H Edelbrock; L P Brennan; C M Grushkin; E Lieberman
Journal:  J Pediatr       Date:  1970-03       Impact factor: 4.406

Review 7.  Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.

Authors:  T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

8.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

9.  Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L S Fung; Philip J O'Connell; Jeremy R Chapman; Richard D M Allen
Journal:  Transplantation       Date:  2004-08-27       Impact factor: 4.939

10.  A personal history of the CAMPATH-1H antibody.

Authors:  Herman Waldmann
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more
  18 in total

1.  Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction.

Authors:  Ron Shapiro; Amit Basu; Henkie P Tan; Claire Morgan; Vivek Sharma; Deanna Blisard; Parmjeet S Randhawa; Igor Dvorchik; Jerry McCauley; Demetrius Ellis; J Wallis Marsh; Steven Webber; Geoffrey Kurland; Kenneth McCurry; Kareem Abu-Elmagd; George Mazariegos; Thomas E Starzl
Journal:  Transplantation       Date:  2008-05       Impact factor: 4.939

Review 2.  Immunosuppressive preconditioning or induction regimens : evidence to date.

Authors:  Henkie P Tan; Marc C Smaldone; Ron Shapiro
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Acquired immunologic tolerance: with particular reference to transplantation.

Authors:  Thomas E Starzl
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  The effects of preoperative immunosuppressive therapy on ischemia and reperfusion (I/R) injury in healthy rats.

Authors:  Selcuk Kilinc; Sedat Tan; Efsun Hatice Kolatan; Dane Ruscuklu; Esra Satici; Mehmet Kemiksiz; Lutfi Dalkilic; Umut Eren Erdogdu; Cezmi Karaca
Journal:  Int Urol Nephrol       Date:  2013-09-08       Impact factor: 2.370

5.  Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.

Authors:  Ngoc L Thai; Akhtar Khan; Kusum Tom; Deanna Blisard; Amit Basu; Henkie P Tan; Amadeo Marcos; John J Fung; Thomas E Starzl; Ron Shapiro
Journal:  Transplantation       Date:  2006-12-27       Impact factor: 4.939

6.  Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.

Authors:  Blanche M Chavers; Y Catherine Chang; Kristen J Gillingham; Arthur Matas
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

7.  Kidney after nonrenal transplantation-the impact of alemtuzumab induction.

Authors:  Ron Shapiro; Amit Basu; Henkie P Tan; Claire Morgan; Vivek Sharma; Deanna Blisard; Parmjeet S Randhawa; Igor Dvorchik; Jerry McCauley; Demetrius Ellis; J Wallis Marsh; Steven Webber; Geoffrey Kurland; Kenneth R McCurry; Kareem Abu-Elmagd; George Mazariegos; Thomas E Starzl
Journal:  Transplantation       Date:  2009-09-27       Impact factor: 4.939

Review 8.  Steroid withdrawal in renal transplantation.

Authors:  Ryszard Grenda
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

Review 9.  Induction therapy in pediatric renal transplant recipients: an overview.

Authors:  Asha Moudgil; Dechu Puliyanda
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  Mycobacterium haemophilum infection after alemtuzumab treatment.

Authors:  Mini Kamboj; Eddie Louie; Timothy Kiehn; Genovefa Papanicolaou; Michael Glickman; Kent Sepkowitz
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.